Fatty acid synthesis is essential for survival of Cryptococcus neoformans and a potential fungicidal target.
Fatty acid synthase in the yeast Cryptococcus neoformans is composed of two subunits encoded by FAS1 and FAS2 genes. We inserted a copper-regulated promoter (P(CTR4-2)) to regulate FAS1 and FAS2 expression in Cryptococcus neoformans (strains P(CTR4-2)/FAS1 and P(CTR4-2)/FAS2, respectively). Both mutants showed growth rates similar to those of the wild type in a low-copper medium in which FAS1 and FAS2 were expressed, but even in the presence of exogenous fatty acids, strains were suppressed in growth under high-copper conditions. The treatment of C. neoformans with fluconazole was shown to have an increased inhibitory activity and even became fungicidal when either FAS1 or FAS2 expression was suppressed. Furthermore, a subinhibitory dose of fluconazole showed anticryptococcal activity in vitro in the presence of cerulenin, a fatty acid synthase inhibitor. In a murine model of pulmonary cryptococcosis, a tissue census of yeast cells in P(CTR4-2)/FAS2 strain at day 7 of infection was significantly lower than that in mice treated with tetrathiomolybdate, a copper chelator (P < 0.05), and a yeast census of P(CTR4-2)/FAS1 strain at day 14 of infection in the brain was lower in the presence of more copper. In fact, no positive cultures from the brain were detected in mice (with or without tetrathiomolybdate treatment) infected with the P(CTR4-2)/FAS2 strain, which implies that this mutant did not reach the brain in mice. We conclude that both FAS1 and FAS2 in C. neoformans are essential for in vitro and in vivo growth in conditions with and without exogenous fatty acids and that FAS1 and FAS2 can potentially be fungicidal targets for C. neoformans with a potential for synergistic behavior with azoles.
Chayakulkeeree
Methee
M
Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, NC 27710, USA.
Rude
Thomas H
TH
Toffaletti
Dena L
DL
Perfect
John R
JR
D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology*; D001393:Azoles / Q000494:pharmacology; D001921:Brain / Q000382:microbiology; D002569:Cerulenin / Q000494:pharmacology; D015169:Colony Count, Microbial; D003300:Copper / Q000502:physiology; D003453:Cryptococcosis / Q000188:drug therapy / Q000382:microbiology; D003455:Cryptococcus neoformans / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism*; D004271:DNA, Fungal / Q000096:biosynthesis / Q000235:genetics; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D064429:Fatty Acid Synthases / Q000037:antagonists & inhibitors* / Q000235:genetics; D005227:Fatty Acids / Q000096:biosynthesis*; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000235:genetics; D008168:Lung / Q000382:microbiology; D051379:Mice; D008826:Microbial Sensitivity Tests; D010641:Phenotype; D011401:Promoter Regions, Genetic / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction
D000935:Antifungal Agents; D001393:Azoles; D004271:DNA, Fungal; D004791:Enzyme Inhibitors; D005227:Fatty Acids; D007527:Isoenzymes; D002569:Cerulenin; D003300:Copper; D064429:Fatty Acid Synthases
Annu Rev Nutr. 2001;21:97-119
11375431
Laryngoscope. 2001 Apr;111(4 Pt 1):696-701
11359142
Microbiology. 2002 Aug;148(Pt 8):2607-15
12177355
Infect Immun. 2002 Oct;70(10):5684-94
12228298
J Nat Prod. 2002 Dec;65(12):1909-14
12502337
Eukaryot Cell. 2003 Dec;2(6):1336-49
14665467
Yeast. 2004 Aug;21(11):919-26
15334556
Microbiol Mol Biol Rev. 2004 Sep;68(3):501-17, table of contents
15353567
Eukaryot Cell. 2004 Oct;3(5):1249-60
15470254
Mol Gen Genet. 1986 Jun;203(3):479-86
3528750
J Biol Chem. 1988 Sep 5;263(25):12315-25
2900835
J Biol Chem. 1989 Oct 5;264(28):16537-44
2674136
Eur J Biochem. 1992 Feb 1;203(3):607-14
1735446
J Bacteriol. 1993 Mar;175(5):1405-11
8444802
J Biol Chem. 1993 May 25;268(15):10946-52
8098706
Microbiology. 1996 Sep;142 ( Pt 9):2509-14
8828218
Infect Immun. 1997 Feb;65(2):829-32
9009352
Invest Ophthalmol Vis Sci. 2005 Jan;46(1):299-303
15623788
Eukaryot Cell. 2005 Feb;4(2):487-9
15701811
Nat Rev Microbiol. 2005 Oct;3(10):753-64
16132036
FEMS Yeast Res. 2006 Jun;6(4):469-79
16696643
Infect Dis Clin North Am. 2006 Sep;20(3):507-44, v-vi
16984867
J Clin Invest. 2007 Mar;117(3):794-802
17290306
J Biol Chem. 2001 Oct 5;276(40):37051-9
11477098